Market Publishers is pleased to inform its valued clients that La Merie Publishing is currently running an open-end discount offer on its package of 2 related T-Cell Receptor (TCR)-Based Immunotherapy reports. Now this package is available at a 33% discount: US$ 5,257.00 – US$ 3,505.00.
The introduction of T-Cell Receptor (TCR)-based therapeutic cells along with recombinant antibodies or antibody fusion proteins has brought cancer therapeutics to a new level. Both treatment options target intracellular components that are considered to be three-four times more frequent in comparison to surface proteins. But, these intracellular cancer targets are inaccessible to CAR T-cell or monoclonal antibody therapies. TCR engineered T-cells act using the cytotoxicity of T-cells, while antibodies act through their intrinsic effects (CDC, ADCC) or by boosting them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.
Reports in “TCR-Based Antibody and T-Cell Immunotherapy” Package Include:
Detailed descriptions and tables of contents of these reports together with sample pages are available on the respective product pages.
For more details on this offer, don’t hesitate to contact our Sales Manager by email or by phone at +44 20 8123 2220.
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of ... or T-cell redirecting bispecific antibodies. This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy ...